Thromboembolic Risk in Ulcerative Colitis Patients on Advanced Therapy: A Real-World Data Analysis
Vedolizumab demonstrated a favorable thromboembolic and cardiovascular safety profile compared with TNF inhibitors, whereas tofacitinib did not increase the risk at either dose. Concomitant 5-aminosalicylic acid may have a preventive effect against VTE. These findings may aid therapeutic decision-making for UC patients with elevated thrombotic risk.
Authors
- Masaki Ominami (ORCID: https://orcid.org/0000-0002-9692-0420)
- Shusei Fukunaga (ORCID: https://orcid.org/0000-0002-9336-8271)
- Yuji Nadatani
- Rieko Nakata (ORCID: https://orcid.org/0000-0001-9977-7239)
- Koji Fujimoto (ORCID: https://orcid.org/0000-0003-1209-7949)
- Hirotsugu Maruyama (ORCID: https://orcid.org/0000-0002-8728-8101)
- Yasuhiro Fujiwara (ORCID: https://orcid.org/0009-0008-7303-1699)
- Koji Otani (ORCID: https://orcid.org/0000-0001-9075-6415)
- Shuhei Hosomi (ORCID: https://orcid.org/0000-0002-8808-5672)
- Yumie Kobayashi (ORCID: https://orcid.org/0000-0002-5747-6697)
- Fumio Tanaka (ORCID: https://orcid.org/0000-0002-9186-1249)
- Yu Nishida (ORCID: https://orcid.org/0000-0003-3369-5059)
Institutions
- Osaka City University (JP)
- Osaka Metropolitan University (JP)
- Tokyo Metropolitan University (JP)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2025-11-19
- DOI
- https://doi.org/10.1093/ibd/izaf302
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82